Richmond Pharmacology

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Amyloidosis4 trials
• Heart failure2 trials
• Deep vein thrombosis and pulmonary embolism1 trial
• Familial hypercholesterolaemia1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• High blood pressure1 trial

Phase

• Phase 13 trials
• Phase 33 trials
• Phase 1/22 trials

Status

• Recruiting7 trials
• Completed2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Ionis Pharmaceuticals, Inc.3 trials
• CRISPR Therapeutics AG2 trials
• City Therapeutics1 trial
• Intellia Therapeutics1 trial
• Novo Nordisk A/S1 trial
• and 2 more

Running trials

• Recruiting

  A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension

  NCT07758634· Phase 1/2· CRISPR Therapeutics AG· Source

  Contact: Clinical Trials

• Recruiting

  Study of TGM-312-SC01 in Healthy Participants and Adults With MASH

  NCT07427680· Phase 1/2· Tangram Therapeutics Plc· Source

  Contact: Study Director

• Recruiting

  A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in Healthy Adults, Adults With FV Leiden or Prothrombin G20210A Mutation, and Adults With a History of Provoked Venous Thromboembolism

  NCT07430397· Phase 1· City Therapeutics· Source

  Contact: Dr. Ulrike Lorch

• Recruiting

  A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure

  NCT07218627· Phase 1· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care

  NCT06809686· Richmond Research Institute· Source

  Contact: Volunteer Recruitment Team

• Recruiting

  A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

  NCT07491172· Phase 1· CRISPR Therapeutics AG· Source

  Contact: Volunteer Recruitment Team

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

  Contact: Trial Manager at Intellia

• Enrolling by invitation

  An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

  NCT05667493· Phase 3· Ionis Pharmaceuticals, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Heart failure2 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Familial hypercholesterolaemia1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• High blood pressure1 recruiting

Closed trials

• Completed

  CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

  NCT06073574· Ionis Pharmaceuticals, Inc.· Source

• Completed

  CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

  NCT04136171· Phase 3· Ionis Pharmaceuticals, Inc.· Source